Related Experiment Videos
Opsomyoclonus and neuroblastoma. Response to ACTH
Clinical Pediatrics
|July 1, 1979
Summary
For children with neuroblastoma and recurring opsomyoclonus, tumor re-evaluation is crucial. If no tumor is found, adrenocorticotropic hormone (ACTH) therapy may benefit those with severe symptoms impacting development.
Area of Science:
- Pediatric Oncology
- Neurology
- Immunology
Background:
- Neuroblastoma is a common childhood cancer.
- Opsomyoclonus is a rare neurological disorder often associated with neuroblastoma.
- Recurrent or persistent opsomyoclonus after surgery indicates potential residual disease or a paraneoplastic process.
Observation:
- Children with neuroblastoma experiencing recurrent or persistent opsomyoclonus require thorough tumor re-evaluation.
- In cases where no detectable tumor is present, alternative treatment strategies should be considered.
Findings:
- Adrenocorticotropic hormone (ACTH) therapy is a potential treatment option for opsomyoclonus.
- ACTH therapy should be considered for patients with severe symptomatology that compromises normal development.
Implications:
- Early identification and management of recurrent opsomyoclonus are vital for improving outcomes in neuroblastoma patients.
- ACTH therapy offers a therapeutic avenue for managing severe opsomyoclonus when tumor is undetectable, potentially preserving normal development.
- This approach highlights the complex interplay between neuroblastoma, the immune system, and neurological function.